ACTIVATION OF NF-$\kappa$B IN THE CISPLATIN-INDUCED APOPTOSIS OF ORAL SQUAMOUS CELL CARCINOMA

구강편평세포암종에서의 Cisplatin 유도 아폽토시스에서의 NF-$\kappa$B의 활성화

  • Seo, Jong-Chun (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Sung, Iel-Yong (Dept. of Oral & Maxillofacial Surgery, Medical College of Ulsan University) ;
  • Kim, Jong-Roul (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
  • 서종천 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 성일용 (울산대학교 의과대학 울산대학교병원 치과/구강악안면외과) ;
  • 김종렬 (부산대학교 치과대학 구강악안면외과학교실)
  • Published : 2006.04.30

Abstract

Purpose: This study was done to confirm the role of NF-$\kappa$B in cisplatin-induced apoptosis of oral squamous cell carcinoma. Materials and Methods: Five cell lines originated from different oral cancer patients were tested for the apoptosis by the treatment of cisplatin. These cells showed different degree of cisplatin-resistance and the order is OSCC-2>OSCC-3>OSCC-5> OSCC-1>OSCC-4. OSCC-2 and OSCC-4 cells were assayed for the apoptosis by measuring DNA fragmentation and TUNEL staining after cisplatin treatment. While OSCC-4 cells showed apoptosis, OSCC-2 cells showed no or very slight apoptosis by cisplatin treatment. Next, It was determined whether NF-$\kappa$B activation is required in mediating cisplatin-induced apoptosis of OSCC-4. Result: The result was that elevated NF-$\kappa$B activity mediated cisplatin-induced apoptosis. Conclusion: In conclusion, these findings suggest that NF-$\kappa$B activation is essential to cisplatin-induced apoptosis and it may be involved in cisplatin resistance in OSCC cells.

References

  1. Andrews PA, Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2(2):35-43. Review
  2. Hromas RA, North JA, Burns CP: Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett 1987;36(2):197-201 https://doi.org/10.1016/0304-3835(87)90091-7
  3. Moorehead RA, Singh G: Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000;15;59(4):337-45
  4. Fokstuen T, Rabo YB, Zhou JN, Karlson J, Platz A, et al: The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anticancer Res 1997;17(4A):2347-52
  5. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2(8-9):275-80. Review https://doi.org/10.1016/S1535-6108(02)00161-7
  6. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, et al: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol 2002;15;63(8):1423-30
  7. Rong R, He Q, Liu Y, Sheikh MS, Huang Y: TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3- kinase/Akt and NF-kappaB signaling pathway. Oncogene 2002;7;21(7):1062-70
  8. Rayet B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;22;18(49):6938-47. Review https://doi.org/10.1038/sj.onc.1203221
  9. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance which can be overcome by NF-kappaB inhibition. Oncogene 2000;5;19(42):4936- 40 https://doi.org/10.1038/sj.onc.1203861
  10. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19(9):5923-9 https://doi.org/10.1128/MCB.19.9.5923
  11. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, et al: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997;16;15(16):1987-94 https://doi.org/10.1038/sj.onc.1201373
  12. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, et al: Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa Bbinding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995;26;92(20):9328-32
  13. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, et al: Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 1997;8;94(14):7531-6
  14. Tong L, Perez-Polo JR: Transcription factor DNA binding activity in PC12 cells undergoing apoptosis after glucose deprivation. Neurosci Lett 1995;26;191(3):137-40 https://doi.org/10.1016/0304-3940(95)11557-D
  15. Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K: Bcl-2 downregulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 1996;134(1):13-23 https://doi.org/10.1083/jcb.134.1.13
  16. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, et al: NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;28;276(52):48921-9. Epub 2001 Oct 25 https://doi.org/10.1074/jbc.M108674200
  17. Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, et al: Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001;29;20(55):7965-75 https://doi.org/10.1038/sj.onc.1204985
  18. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, et al: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001;3(4):409-16 https://doi.org/10.1038/35070096
  19. Zheng Y, Ouaaz F, Bruzzo P, Singh V, Gerondakis S, et al: NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J Immunol 2001;15;166(8):4949-57 https://doi.org/10.4049/jimmunol.166.8.4949
  20. Kim SY, Chu KC, Lee HR, Lee KS, Carey TE: Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol 1997;117(5):775-84 https://doi.org/10.3109/00016489709113477
  21. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, et al: 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;1;169(9):4882-8 https://doi.org/10.4049/jimmunol.169.9.4882
  22. Timmer-Bosscha H, Mulder NH, de Vries EGL: Modulation of cisdiamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992;66(2):227-38. Review https://doi.org/10.1038/bjc.1992.249
  23. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;1;274(5288):782-4 https://doi.org/10.1126/science.274.5288.782
  24. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;1;274(5288):787-9 https://doi.org/10.1126/science.274.5288.787
  25. Wang CY, Mayo MW, Baldwin AS Jr: TNF- and cancer therapyinduced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;1;274(5288):784-7 https://doi.org/10.1126/science.274.5288.784
  26. Bian X, Opipari AW Jr, Ratanaproeksa AB, Boitano AE, Lucas PC, et al: Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem 2002;1;277(44):42144-50. Epub 2002 Aug 26 https://doi.org/10.1074/jbc.M203891200
  27. Panet H, Barzilai A, Daily D, Melamed E, Offen D: Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem 2001;77(2):391-8 https://doi.org/10.1046/j.1471-4159.2001.00213.x
  28. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, et al: NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999;5(5):554-9 https://doi.org/10.1038/8432
  29. Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, et al:. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 2000;7(10):1315-23 https://doi.org/10.1038/sj.cgt.0241
  30. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, et al: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998;1(4):543-51 https://doi.org/10.1016/S1097-2765(00)80054-4
  31. Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, et al: TRAIL and inhibitors of apoptosis are opposing determinants for NFkappaB- dependent, genotoxin-induced apoptosis of cancer cells. Oncogene 2002;10;21(2):260-71 https://doi.org/10.1038/sj.onc.1205048
  32. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J: Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001;15;167(6):3164-73 https://doi.org/10.4049/jimmunol.167.6.3164
  33. Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC: NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 2001;2;276(44):40385-8. Epub 2001 Sep 11 https://doi.org/10.1074/jbc.C100501200
  34. Nicholson DW, Thornberry NA: Caspases: killer proteases. Trends Biochem Sci 1997;22(8):299-306. Review https://doi.org/10.1016/S0968-0004(97)01085-2